Sage Therapeutics, Inc. (NASDAQ:SAGE - Free Report) - Research analysts at Wedbush lifted their FY2024 earnings estimates for shares of Sage Therapeutics in a research report issued to clients and investors on Thursday, January 23rd. Wedbush analyst L. Chico now expects that the biopharmaceutical company will earn ($7.01) per share for the year, up from their previous forecast of ($7.06). Wedbush currently has a "Neutral" rating and a $8.00 target price on the stock. The consensus estimate for Sage Therapeutics' current full-year earnings is ($6.47) per share. Wedbush also issued estimates for Sage Therapeutics' Q4 2024 earnings at ($1.98) EPS, Q1 2025 earnings at ($1.24) EPS, Q2 2025 earnings at ($1.00) EPS, Q3 2025 earnings at ($0.95) EPS, Q4 2025 earnings at ($0.93) EPS, FY2025 earnings at ($4.11) EPS, FY2026 earnings at ($2.63) EPS, FY2027 earnings at ($0.36) EPS and FY2028 earnings at ($0.08) EPS.
Other equities analysts also recently issued research reports about the company. Raymond James reiterated a "market perform" rating on shares of Sage Therapeutics in a report on Thursday, October 10th. Stifel Nicolaus lowered their target price on shares of Sage Therapeutics from $10.00 to $6.00 and set a "hold" rating on the stock in a research note on Monday, December 16th. TD Cowen dropped their target price on shares of Sage Therapeutics from $10.00 to $9.00 and set a "hold" rating on the stock in a report on Thursday, November 21st. Oppenheimer decreased their price target on shares of Sage Therapeutics from $9.00 to $8.00 and set a "market perform" rating for the company in a report on Wednesday, October 30th. Finally, Bank of America lowered their price target on Sage Therapeutics from $11.00 to $6.00 and set an "underperform" rating on the stock in a research report on Wednesday, October 9th. Three analysts have rated the stock with a sell rating, sixteen have assigned a hold rating and two have given a buy rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Hold" and a consensus target price of $10.53.
Check Out Our Latest Research Report on SAGE
Shares of NASDAQ SAGE opened at $7.10 on Monday. The business's 50-day simple moving average is $5.83 and its 200-day simple moving average is $7.31. Sage Therapeutics has a 52 week low of $4.62 and a 52 week high of $27.67. The firm has a market cap of $434.31 million, a price-to-earnings ratio of -1.27 and a beta of 0.91.
Sage Therapeutics (NASDAQ:SAGE - Get Free Report) last posted its earnings results on Tuesday, October 29th. The biopharmaceutical company reported ($1.53) EPS for the quarter, missing the consensus estimate of ($1.52) by ($0.01). Sage Therapeutics had a negative return on equity of 50.29% and a negative net margin of 317.29%. The business had revenue of $11.87 million for the quarter, compared to analyst estimates of $10.80 million. During the same period in the previous year, the company earned ($2.81) earnings per share. The company's quarterly revenue was up 337.1% compared to the same quarter last year.
A number of institutional investors have recently added to or reduced their stakes in SAGE. RTW Investments LP lifted its position in shares of Sage Therapeutics by 2.0% during the 3rd quarter. RTW Investments LP now owns 5,591,700 shares of the biopharmaceutical company's stock worth $40,372,000 after buying an additional 111,123 shares during the period. State Street Corp lifted its holdings in shares of Sage Therapeutics by 18.2% during the third quarter. State Street Corp now owns 2,926,239 shares of the biopharmaceutical company's stock valued at $21,127,000 after acquiring an additional 451,377 shares during the period. Geode Capital Management LLC boosted its stake in shares of Sage Therapeutics by 0.3% in the 3rd quarter. Geode Capital Management LLC now owns 1,242,854 shares of the biopharmaceutical company's stock valued at $8,975,000 after purchasing an additional 3,757 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its stake in shares of Sage Therapeutics by 10.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 452,193 shares of the biopharmaceutical company's stock valued at $3,265,000 after purchasing an additional 43,617 shares in the last quarter. Finally, Squarepoint Ops LLC increased its position in shares of Sage Therapeutics by 1,112.0% during the 2nd quarter. Squarepoint Ops LLC now owns 313,407 shares of the biopharmaceutical company's stock worth $3,404,000 after purchasing an additional 287,549 shares in the last quarter. 99.22% of the stock is owned by institutional investors and hedge funds.
Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Sage Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sage Therapeutics wasn't on the list.
While Sage Therapeutics currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.